A trial with IV iron if Hb increase or ESA dose reduction is desired and SF ≤ 500 ng/mL and TSAT ≤ 30% ND-CKD: When Hb<10 g/dL: Individualize decision based on the rate of fall of Hb, risks and symptoms. DD-CKD: When Hb 9-10 g/dL.  Avoid Hb < 9 g/dl. Here, GSTM1 is linked to chronic kidney disease.